Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2024 | $8.00 | Outperform | Leerink Partners |
| 4/11/2024 | $10.00 | Overweight | Piper Sandler |
| 3/28/2024 | $7.00 | Outperform | Raymond James |
Leerink Partners initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00
Piper Sandler initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $10.00
Raymond James initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00
Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs)Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrollingContinues to anticipate requesting a pre-New Drug Application (NDA) meeting before the end of the third quarter
JMP Securities analyst Jason Butler reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Market Outperform and maintains $9 price target.
On Tuesday, Aquestive Therapeutics Inc (NASDAQ:AQST) released topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm (epinephrine) Sublingual Film. Anaphylm is the company’s first and only orally administered epinephrine prodrug product candidate under development for severe life-threatening allergic reactions, including anaphylaxis. In March, Aquestive Therapeutics released topline clinical data from its Phase 3 PK study of Anaphylm, meeting all primary and secondary pharmacokinetic endpoints. Pharmacokinetics is the movement of drugs into, through, and out of the body. The single-dose, five-period, randomized crossover study was desi
Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channelsFinished third quarter 2024 with approximately $78 million of cash and reaffirms cash runway into 2026To host investment community conference call at 8:00 am ET on November 5, 2024 WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative sci
WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2024 and provide an update on recent developments in its business after market close on Monday, November 4, 2024. Management will host a conference call for investors at 8:00 a.m. ET on Tuesday, November 5, 2024. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
Late-stage pipeline program, Anaphylm™ (epinephrine) Sublingual Film, remains on track for a near-term New Drug Application (NDA) submission to the FDAExpanded sales coverage for Libervant™ (diazepam) Buccal Film for patients between ages two to five with national retail distribution anticipated in the fourth quarter 2024Anticipates holding epinephrine prodrug technology investor day in the coming monthsFinishes the second quarter 2024 with cash and cash equivalents of approximately $90 million and reaffirms cash runway into 2026To host investment community conference call at 8:00 am ET on August 7, 2024 WARREN, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:
4/A - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4/A - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4/A - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
10-Q - Aquestive Therapeutics, Inc. (0001398733) (Filer)
SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)
WAQRREN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in November and December 2024 as follows: Jefferies London Annual Healthcare Conference: management will be available for 1x1 meetings on Tuesday, November 19th through Thursday, November 21stPiper Sandler's 35th Annual Healthcare Conference: fireside chat to take place on Wednesday, December 4th at 1:30pm ET; management wil
Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal Film for patients aged 2-5 available through retail distribution channelsFinished third quarter 2024 with approximately $78 million of cash and reaffirms cash runway into 2026To host investment community conference call at 8:00 am ET on November 5, 2024 WARREN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative sci
Initial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or pharmacodynamics (PD), with all results comparable to epinephrine injectionData demonstrates Anaphylm offers a consistent and permissive method of drug delivery in anaphylaxis management WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that a subsequent analysis of the data from the pivotal study of its product candidate Anaphylm™ (epinephrine)
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public
WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p
Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company. NDA Filing for Libervant for Pediatric PopulationAquestive submitted a N